Beranda › Miastenia Gravis › South Carolina
Uji klinis Miastenia Gravis di South Carolina
7 studi untuk Miastenia Gravis mencari peserta di lokasi di South Carolina.
Kota di South Carolina
Teks studi resmi (Bahasa Inggris)
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- TG Therapeutics Investigational Trial Site, Greenville
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07673744Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Clinical Trials of South Carolina - Charleston, Charleston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06463587A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- Clinical Trials of South Carolina - Neurology, Charleston
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT07501702Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1030, Charleston
- Site Number - 1015, Charleston
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07039916A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Medical University of South Carolina, Charleston
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT04951622A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
- Medical University of South Carolina, Charleston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Feb 2026 · NCT06298565Vitaccess Real MG Registry
- Medical University South Carolina, Charleston
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2025 · NCT06064461Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.